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Abstract
Background: Human populations exposed to low malaria transmission present particular severe risks of malaria
morbidity and mortality. In addition, in a context of low-level exposure to Anopheles vector, conventional entomological
methods used for sampling Anopheles populations are insufficiently sensitive and probably under-estimate the real risk of
malaria transmission. The evaluation of antibody (Ab) responses to arthropod salivary proteins constitutes a novel tool
for estimating exposure level to insect bites. In the case of malaria, a recent study has shown that human IgG responses
to the gSG6-P1 peptide represented a specific biomarker of exposure to Anopheles gambiae bites. The objective of this
study was to investigate if this biomarker can be used to estimate low-level exposure of individuals to Anopheles vector.
Methods: The IgG Ab level to gSG6-P1 was evaluated at the peak and at the end of the An. gambiae exposure season in
children living in Senegalese villages, where the Anopheles density was estimated to be very low by classical entomological
trapping but where malaria transmission occurred during the studied season.
Results: Specific IgG responses to gSG6-P1 were observed in children exposed to very low-level of Anopheles bites. In
addition, a significant increase in the specific IgG Ab level was observed during the Anopheles exposure season whereas
classical entomological data have reported very few or no Anopheles during the studied period. Furthermore, this
biomarker may also be applicable to evaluate the heterogeneity of individual exposure.
Conclusion: The results strengthen the hypothesis that the evaluation of IgG responses to gSG6-P1 during the season
of exposure could reflect the real human contact with anthropophilic Anopheles and suggest that this biomarker of low
exposure could be used at the individual level. This promising immuno-epidemiological marker could represent a useful
tool to assess the risk to very low exposure to malaria vectors as observed in seasonal, urban, altitude or travellers
contexts. In addition, this biomarker could be used for the surveillance survey after applying anti-vector strategy.
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Background
The re-emergence of mosquito-borne diseases represents a
major public health problem in developing and devel-
oped countries, highlighting the need to develop new
tools to assess the risk of disease transmission. Malaria has
a broad range of different epidemiological profiles,
depending on the distribution and vectorial capacity of
the mosquito vectors, environmental conditions, and the
degree of protective immunity acquired by the exposed
population. Control strategies need to be formulated
according to transmission and exposure patterns, and the
behaviour of the relevant Anopheles species.
The WHO reported that 29% of the world's population
lives in areas where the level of malaria transmission is
low [1]. This mainly corresponds to strictly seasonal trans-
mission, or highland (> 1,500 m), arid (< 1,000 mm rain-
fall/year) and urban areas. For example, urban malaria is
now becoming a serious public health problem in several
rapidly growing African cities (largely due to migration
from the countryside)[2]. Despite exposure to low num-
bers of Anopheles vectors, people in these settings could be
at a high risk of malarial morbidity and mortality because
protective immunity is acquired so slowly. Currently,
strategies for malaria surveillance and control are of lim-
ited efficiency in these epidemiological low-level contexts.
Assessing the risk of malaria is based on entomological
parameters (the entomological inoculation rate [EIR])
and parasitological methods (Plasmodium  density in
human blood). In a context of low transmission, parasito-
logical methods are limited and need large-scale field
evaluation. The evaluation of Anopheles  density using
entomological methods (traps, household/indoor spray-
ings, human-landing catches, etc.), the first step in an EIR
assessment, is not sensitive enough to permit estimation
of low-level exposure to Anopheles: the total number of
Anopheles collected is too low to estimate real exposure
and thus the risk of malaria transmission. In addition,
such methods are mainly applicable at the population
level and do not enable the evaluation of the heterogene-
ity of individual exposure. A simple, rapid, highly sensi-
tive tool is, therefore, needed to evaluate low-level
exposure to Anopheles bites and the risk of malaria in such
populations.
It has been proposed that the level of exposure to vector
bites could be evaluated by measuring the antibody (Ab)
response to arthropod saliva in exposed populations
[3,4]. The salivary proteins of haematophagous insects
have a dual role to facilitate blood-feeding: their pharma-
cological activities counteract human defense mecha-
nisms (inflammation and blood clotting); and their
immunological activities modulate the human host's
immune response [5,6]. Some of these salivary proteins
are immunogenic and induce a specific Ab response [7,8].
Several studies have shown that the Ab response specific
to salivary proteins could be used as a marker of exposure
to vector-borne diseases in individuals bitten by arthro-
pod vectors, e.g. ticks [9], sandflies [10], Triatoma [11],
Glossina [12] and Aedes [13,14]. As far as Anopheles spp.
and malaria transmission are concerned, early epidemio-
logical studies showed that individuals living in malaria-
endemic areas developed Ab responses specific to salivary
proteins that represent a marker of exposure to Anopheles
bites [15,16].
Recently, a study has identified the SG6 salivary protein as
an encouraging candidate as serological marker of expo-
sure. The SG6 was previously reported i) specific to the
Anopheles genus [17,18] and ii) antigenic [19]. By a step-
by-step approach, coupling bioinformatic and immuno-
epidemiological approaches, the gSG6-P1 peptide
(derived from the gSG6 salivary protein of Anopheles gam-
biae) was defined and validated as a potential immuno-
epidemiological marker specific to An. gambiae exposure
[20]. This peptide appears to meet several of the require-
ments expected of such an exposure marker. First, it
appears to be specific to the Anopheles genus and would
not be expected to cross-react with epitopes from other
proteins (from the main Diptera species or pathogens).
Second, it is synthetic and can, therefore, be used to
develop a reproducible immunological assay. Third, it
elicits a specific Ab response, which correlates positively
with the level of exposure to An. gambiae bites.
The aim of this work was to evaluate the pertinence of the
gSG6-P1 biomarker in areas where this is a low level of
exposure to An. gambiae. To this end, the study was con-
ducted in Senegal where malaria transmission is strictly
seasonal and especially in villages where few or no An.
gambiae were collected by classical entomological meth-
ods but where a malaria transmission occurred. This study
focused on IgG Ab responses to gSG6-P1 peptide in chil-
dren having had minimal exposure to An. gambiae,
between the peak and the end of the transmission season.
Methods
Study population
The study was conducted in Niakhar, a rural district of
central Senegal. This area is characterized by a dry savan-
nah with a rainy season from July to October. This area is
typical of the Sahel and sub-Sahel regions of Africa, where
malaria is unstable with most Plasmodium falciparum
transmission occurring between September and Novem-
ber [21].
Sera were available from a clinical trial on seasonal inter-
mittent preventive treatment (IPT) for prevention of
malaria performed in 2002 in children aged six weeks to
sixty months [22]. Pairs of sera from a sub-sample of theseMalaria Journal 2009, 8:198 http://www.malariajournal.com/content/8/1/198
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children were available from both the peak (September)
and the end (December) of the exposure season to Anoph-
eles, as previously described [15]. In September and in
December, thick blood smears were collected from each
individual involved in the clinical trial. P. falciparum prev-
alences (positive thick blood smears) were assessed for all
children living in the six studied villages (nSeptember = 403
and nDecember = 388), assuming an average white blood-
cell count of 8,000 per μL. In addition, the outcome of
malaria morbidity from September to December was
reported from all children residing in the six studied vil-
lages; clinical malaria was defined as an axillary tempera-
ture  ≥ 38°C and the presence of P. falciparum with a
density > 3,000 parasites/μL of blood (thick smear)
[15,22]. Sixty-one children from the placebo group were
selected as a sub-sample for the immunological analysis
in both September and December 2002.
Both the trial on malaria treatment and this study fol-
lowed ethical principles as stipulated in the Edinburgh
revision of the Helsinki Declaration, and were approved
by the Ethics Committees of the Ministry of Health of Sen-
egal (August 2002 and May 2003, respectively) and of the
IRD (Institute of Research for the Development) (January
2004). The malaria treatment trial was approved by the
Ethics Committee of the London School of Hygiene and
Tropical Medicine in June 2002.
Entomological data
Entomological data were collected every month between
September and December 2002 in the six studied villages
in the Niakhar area. Indoor samplings by light traps (CDC
miniature light trap) were used to estimate Anopheles den-
sities. Every month, entomological sampling was carried
out in two houses per village for two consecutive nights.
The density of Anopheles per night per trap was calculated
each month for each village by dividing the total number
of mosquitoes caught by the total trap-night involved.
Salivary peptide gSG6-P1
The gSG6-P1 peptide was designed using bioinformatics
to maximize its Anopheles specificity and its antigenicity,
as previously described [20]. The gSG6-P1 peptide was
synthesized, purified (> 80%) by Genosys (Sigma-Geno-
sys, Cambridge, UK) and biotin-conjugated (N-terminal).
All peptides were shipped in lyophilized form and then
resuspended in 0.22 μm ultra-filtered water and frozen in
aliquots at -80°C until use.
Evaluation of human IgG antibody levels (ELISA)
ELISAs were carried out on the sera to measure IgG Ab
level reacting to the gSG6-P1 antigen. Maxisorp plates
(Nunc, Roskilde, Denmark) were coated with gSG6-P1
(20 μg/mL) in carbonate/bicarbonate buffer. Individual
sera (1:20) were incubated in PBS-Tween 1%. Anti-gSG6-
P1 IgG detection was performed using an HRP goat anti-
human IgG Ab (1:25,000, Nordic Immunology, Tilburg,
Netherlands). Colorimetric development was carried out
using ABTS (2,2'-azino-bis (3-ethylbenzthiazoline 6-sul-
fonic acid) diammonium; Sigma, St Louis, MO) in 50 mM
citrate buffer (pH 4) containing 0.003% H2O2. Optical
Density (OD) was measured at 405 nm. Each test sample
was assessed in duplicate wells and, in parallel, in a blank
well containing no antigen (ODn) to control for non-spe-
cific reactions in the plasma and the reagents. Individual
results were expressed as ΔOD value calculated according
to the formula ΔOD = ODx-ODn, where ODx represents
the mean of individual OD in both antigen wells. The evo-
lution of specific IgG anti gSG6-P1 was also investigated
for each individual during the Anopheles exposure season.
Results are expressed as ΔODseason value calculated accord-
ing to the formula ΔODseason = ΔODDecember - ΔODSeptember.
Statistical analysis
All data were analysed with GraphPad Prism software®
(San Diego, CA, USA). After checking that the results did
not have a normal distribution, the Wilcoxon matched
pair test was used to compare paired sera from September
and December and the non-parametric Kruskal-Wallis test
was used for comparisons between more than two groups.
All differences were considered significant at P < 0.05.
Results
Entomological and parasitological data
In Niakhar area, more than 93% of the anopheline species
belong to the An. gambiae complex as previously reported
[15,21]. Entomological data based on collections from
CDC traps indicated a similar pattern of An. gambiae den-
sity in the six villages during the studied period. The mean
Anopheles  density was very low in September (peak of
exposure) and October to be absent in November and
December (Figure 1). Indeed, 0 to 2.5 Anopheles/trap/
night were only collected during the season and depend-
ing on village.
In contrast, a moderate prevalence of P. falciparum in all
children (placebo group; 05 years old) living in these 6
villages was observed not only in September but also in
December. In September, 24.8% of children presented a
positive thick blood smear (from 11.1% to 41.5%
depending on village). In December the prevalence
decreased to 17.2% (from 9.3 to 33.9% depending on vil-
lage). In addition, 17.6% of the children have developed
a malaria attack during the exposure season (from 12.3%
to 37.8% depending on village).
Specific IgG responses to the gSG6-P1 peptide according 
to age group
In a first analysis, IgG Ab levels specific to the gSG6-P1
peptide were evaluated according to the age of the chil-Malaria Journal 2009, 8:198 http://www.malariajournal.com/content/8/1/198
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dren (sub-sample, n = 61) aged from two to sixty months
at the peak (September) and at the end (December) of the
season of Anopheles exposure. The median of IgG Ab level
against gSG6-P1 differed significantly between age groups
(< 1 to 5 years-old) both in September (P = 0.039) and in
December (P = 0.025). In September, IgG responses were
higher in the youngest children group (≤ 1 year-old),
declining progressively through five years of age. A similar
pattern of IgG level according to age group was observed
in December (Figure 2).
Specific IgG responses to the gSG6-P1 peptide during the 
exposure season to Anopheles bites at the population 
level
The evolution of the specific IgG Ab response to gSG6-P1
was then analysed between September and December in
the same children (Figure 3). In September, a considera-
ble anti-gSG6-P1 IgG response was detected in most of
individuals. In addition, the level of specific IgG Ab was
significantly higher in December compared to September
(P = 0.005) suggesting that the anti-gSG6-P1 IgG response
increases during the exposure season.
Specific IgG responses to the gSG6-P1 peptide during the 
exposure season to Anopheles bites at the individual level
The first analyse was at the population level. As a prelim-
inary approach to establish a biomarker for individual
exposure and behind the natural heterogeneity of individ-
ual exposure, the evolution of the anti-gSG6-P1 IgG
response was individually evaluated for each pair of sera
during the season of Anopheles exposure. For this purpose,
the ΔODseason was defined and used to assess the individ-
ual trend (positive, negative or unchanged) between Sep-
tember and December.
An. gambiae density and P. falciparum prevalence Figure 1
An. gambiae density and P. falciparum prevalence. 
Continuous line indicates the level of exposure to An. gam-
biae, calculated by the arithmetic mean (± SD) of the number 
of An. gambiae collected per trap per night from September 
to December in the six villages. In September and in Decem-
ber, the columns indicate the P. falciparum prevalence in all 
children (nSeptember = 403 and nDecember = 388) from studied 
villages.
IgG response to gSG6-P1 according to age groups Figure 2
IgG response to gSG6-P1 according to age groups. Individual ΔOD in September and in December for children aged 
two to sixty months are presented according to age groups. Bars indicate the median value. Statistical significant differences 
between age groups are indicated (non-parametric Kruskal-Wallis test).Malaria Journal 2009, 8:198 http://www.malariajournal.com/content/8/1/198
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Dissimilar evolutions were observed between individuals.
Indeed, in applying an arbitrary threshold, 36% (22/61)
of the children showed an increase of IgG specific to
gSG6-P1 (ΔODseason > 0.1) and 10% (6/61) showed a
decrease (ΔODseason < -0.1); 54% (33/61), showed no
change (-0.1 < ΔODseason < 0.1) between September to
December (Figure 4A). This result allows establishing a
pertinent threshold to identify the children presenting an
increase of specific Ab reponse. No significant difference
was observed according to age groups in the IgG level evo-
lutions (ΔODseason) between September to December (P =
0.129).
In addition, the individual evolution of the ΔOD can be
assessed. Figure 4B shows individual ΔOD evolution from
September to December from children presenting nega-
tive (down  ΔODseason < -0.1) or positive (up  ΔODseason >
0.1) evolutions.
Discussion
This study focused on a particular and "paradoxal"
malaria area, where P. falciparum transmission occurred in
children during the exposure season, but where the classi-
cal entomological methods indicated that the exposure to
An. gambiae was very low.
As it has been previously demonstrated that the specific
IgG response to the salivary peptide gSG6-P1 was a
biomarker of the exposure level to An. gambiae bites [20],
the present study evaluated if the biomarker could be
applied to detect a very low exposure to An. gambiae in
children. The anti-gSG6-P1 IgG levels in the same children
were followed from the peak (September) to the end
(December) of the exposure season. This present study
indicated that specific IgG response could be detected in
children exposed to very rare bites in the same area of
endemic malaria and presented an individual heterogene-
ity even if they live in the same area of exposure. In partic-
ular, specific IgG Ab were detected in most of exposed
children and the IgG level was higher in December than in
September whereas very few An. gambiae were collected
over this period using classical entomological methods.
Moreover, at the individual level, an increase in specific
IgG Ab was clearly observed in 36% of children during the
Anopheles exposure season (ΔODseason > 0.1). These results
point to the potential of specific IgG responses to the
gSG6-P1 peptide as an immuno-epidemiologic biomarker
of exposure to An. gambiae bites, particularly in areas of
very low exposure, where the sensitivity of current ento-
mological methods is limited. In this particular context, it
Individual IgG antibody levels specific to An. gambiae gSG6-P1  in September and December Figure 3
Individual IgG antibody levels specific to An. gambiae 
gSG6-P1 in September and December. Individual ΔOD 
results are presented and bars indicate the median value for 
each month. Statistical significant differences between 
months are indicated (Wilcoxon matched pair test).
Individual evolution of the IgG response to gSG6-P1 from September to December Figure 4
Individual evolution of the IgG response to gSG6-P1 from September to December. Individual ΔODseason of the 
IgG response specific to gSG6-P1 are presented (A). Individual evolutions of ΔOD from September to December are individu-
ally shown and positive (ΔODseason > 0.1) or negative (ΔODseason < -0.1) evolutions are separately presented (B).Malaria Journal 2009, 8:198 http://www.malariajournal.com/content/8/1/198
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appeared also interesting that this biomarker could be
used to evaluate the heterogeneity of individual exposure
and therefore the individual risks of each child for malaria
transmission.
The very low number of mosquitoes collected by the clas-
sical entomological methods in these specific areas can
represent an inadequate or unreal measure of exposure.
Indeed, it appeared clearly that children living in these vil-
lages were exposed to Anopheles vectors during the studied
season. A considerable prevalence of P. falciparum infec-
tions was observed in these villages in September (11.1%
to 41.5%) and also in December (mean = 17.2%) and
17,6% of children has developed one malaria attack from
September to December. Altogether, these results indi-
cated that an important malaria transmission occurred in
these villages even if entomological methods did not indi-
cate an exposure to Anopheles bites (in regards to few or no
collected An. gambiae). This fact of malaria transmission
indicate that children living in these villages have been
well bitten by Anopheles vectors during the studied period,
as the evaluation of anti-gSG6-P1 IgG response can sug-
gest it.
Unfortunately, Ab responses had not been measured at
the start of the rainy season (June, July), precluding anal-
ysis of the development of the responses from the start to
the end of the Anopheles exposure season. In such areas,
where less than 2.5 Anopheles/trap/night is collected
between September and December (depending on vil-
lage), an increase in IgG level specific to the gSG6-P1 is
observed in 36% of children between the peak and the
end of the exposure season (ΔODseason > 0.1). This could
be due to a high sensitivity and specificity of the gSG6-P1
epitope(s) after a low immunological boost with just a
few bites. Indeed, gSG6 protein was not a major immuno-
genic salivary protein according to immuno-blotting anal-
yses in children exposed to moderate or high level of
Anopheles [23] whereas specific IgG to this antigen has
been reported in travellers who had only been exposed to
Anopheles bites for a short period [19]. Furthermore, in the
same area and period, a previous study had investigated
the specific IgG response to whole An. gambiae saliva [15].
Children living in low exposure villages presented a signif-
icant decrease in anti-saliva IgG between September and
December. In addition, previous results have demon-
strated that the IgG response to another An. gambiae sali-
vary protein (175 kDa) decreased during the exposure
season in the same area [23]. Comparison of results from
children living in the same area indicates that the Ab
responses directed to whole saliva, to several salivary pro-
teins or to the specific peptide differ according to the
exposure intensity. It points to the immuno-sensitivity of
the gSG6-P1 peptide and its suitability as a biomarker of
low exposure to An. gambiae bites, in contrast to whole
saliva or 175 kDa salivary proteins. In particular, the
development of an anti-peptide IgG response could
require repeated but rare Anopheles bites, in contrast to
other proteins or whole saliva which only elicit a response
after many bites, and which waning rapidly even with sus-
tained exposure. Given the half-life of IgG antibodies
(three weeks), the sustained anti-gSG6-P1 IgG response
observed in some children could genuinely be due to
repeated Anopheles bites throughout the studied period.
One major interest to evaluate the An. gambiae exposure
by the approach of IgG response to gSG6-P1 is also the
entire specificity to Anopheles bites. Indeed, the use of this
peptide counteracts the possible cross-reactivity with
shared epitopes on immunogenic salivary proteins from
other arthropods, as previously described [20]. This spe-
cificity and sensitivity to the gSG6-P1 biomarker appeared
to be especially efficient in a context of very low Anopheles
exposure.
Interestingly, it has been reported that the highest specific
IgG levels are seen in the youngest children, waning stead-
ily through the first 60 months. This population of very
young children (<12 months) is probably very weakly
exposed to An. gambiae because of the protective behav-
iour of their mothers against mosquitoes (e.g. bednet pro-
tection during the night). Nevertheless, even the youngest
children may be bitten by Anopheles although the high
specific IgG response observed in this group could also
result from the passive IgG transfer from mother to child
during pregnancy or breastfeeding. It is known that mater-
nal IgG persist in the infant blood for up to nine months
after birth [24] and, at birth, foetal IgG typically some-
what exceeds maternal levels [25]. In this study, the
acquired specific IgG response (induced by exposure to
bites) and passive IgG transfer cannot be differentiate.
This is currently being investigated. The important point
when it comes to defining the validity of this exposure
biomarker is that specific IgG responses to this peptide are
observed in both very young and older children, the main
population at risk of malaria.
In complement to the population approach, the individ-
ual IgG responses were investigated during the exposure
season. In a low exposure context, few Anopheles  are
present and An. gambiae females tend to stay faithful to
particular feeding sites (i.e. the female will return to the
same house to feed thereby increasing clustering) [26].
These factors could increase the heterogeneity of the indi-
vidual exposure risk in a given village. In this study, evo-
lutions in specific IgG anti gSG6-P1 levels during the
Anopheles exposure season seem to discriminate between
those who are being bitten and those who are not.
Conclusion
Taken together, these results indicated that measuring IgG
level specific to gSG6-P1 during the exposure seasonMalaria Journal 2009, 8:198 http://www.malariajournal.com/content/8/1/198
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could be used to evaluate a low level of exposure to Anoph-
eles bites, notably at the individual level. This indicator,
evaluated at just two time points, could be used to identify
those who have been exposed to An. gambiae in very low
exposure areas. This individual approach is complemen-
tary to entomological methods but contributes informa-
tion about real human contact with anthropophilic
Anopheles.
Such biomarker would be particularly relevant in places
where malaria transmission is low, e.g. in foci of urban,
high-altitude or seasonal malaria, and in travellers in
endemic areas. In addition, this indicator of low exposure
could be useful to monitor the risk of re-exposure to
malaria vectors after a vector control campaign (insecti-
cide, bednet) and could applied to other vector-borne dis-
eases (e.g. Aedes-transmitted arboviruses).
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